Journals / Cukurova Medical Journal / 2023 / Cilt: 48 - Sayı: 1

Effect of microsatellite instability on histopathological parameters and prognosis in colon cancers

Kolon kanserlerinde mikrosatellite instabilitenin histopatolojik parametreler ve prognoz üzerine etkisi

Pages
1–10
Publication Date
2023-03-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The presence of TILs exhibited a protective effect (Hazard ratio (HR)=0.446), which decreased the mortality risk by 2.24 times for the follow-up period, while the presence of high TBS increased the risk of mortality by HR=3.22.Conclusion: This study revealed that patients with MSI CRCs may show unique clinicopathological features and should be evaluated using some guiding parameters that will improve survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study was to compare the clinicopathological features, while evaluating the frequency of MSI, and the survival rates in these patients in our patient group with MSI and microsatellite stabil (MSS) colorectal carcinomas (CRCs).Materials and Methods: We retrospectively enrolled 146 patients who underwent colon resection between the years of 2014-2022.
📊
Key Findings & Data:The association of MSI status, presense of tumor-infiltrating lymphocytes (TILs), and tumor budding score with a patient’s survival was assessed by the Kaplan–Meier method and Cox regression analysis.Results: There were 104 (71.2%) MSS cases and, 42 (28.8%) MSI cases. 15 (10.3%) MSI tumors were found to be MSI-low, and 27 (18.5%) to be MSI-high.
💡
Conclusion & Impact:The presence of TILs exhibited a protective effect (Hazard ratio (HR)=0.446), which decreased the mortality risk by 2.24 times for the follow-up period, while the presence of high TBS increased the risk of mortality by HR=3.22.Conclusion: This study revealed that patients with MSI CRCs may show unique clinicopathological features and should be evaluated using some guiding parameters that will improve survival.
🔬Design:Modeling & Simulation
📍Scope:2014-2022 Verileri
⚙️Variables:Kolon kanseri · mikrosatellite instabilite · histopatolojik parametre

Abstract

Purpose: The aim of this study was to compare the clinicopathological features, while evaluating the frequency of MSI, and the survival rates in these patients in our patient group with MSI and microsatellite stabil (MSS) colorectal carcinomas (CRCs).Materials and Methods: We retrospectively enrolled 146 patients who underwent colon resection between the years of 2014-2022. The expression of MSI status was evaluated by immunohistochemistry. The association of MSI status, presense of tumor-infiltrating lymphocytes (TILs), and tumor budding score with a patient’s survival was assessed by the Kaplan–Meier method and Cox regression analysis.Results: There were 104 (71.2%) MSS cases and, 42 (28.8%) MSI cases. 15 (10.3%) MSI tumors were found to be MSI-low, and 27 (18.5%) to be MSI-high. MSI tumors were significantly associated with younger patients (<50), earlier stage (T1-T2), right localization, lower rate of lymph node metastasis, presence of mucinous component and TILs response. The Cox-regression model revealed TILs, tumor budding score, and MSI are variables that significantly affect survival. The presence of TILs exhibited a protective effect (Hazard ratio (HR)=0.446), which decreased the mortality risk by 2.24 times for the follow-up period, while the presence of high TBS increased the risk of mortality by HR=3.22.Conclusion: This study revealed that patients with MSI CRCs may show unique clinicopathological features and should be evaluated using some guiding parameters that will improve survival.

Özet

Amaç: Bu çalışmada, MSİ ile mikrosatellit stabil (MSS) kolorektal karsinomlu (KRK) hasta grubumuzda, klinikopatolojik özellikleri karşılaştırmayı, MSİ sıklığını ve bu hastalarda sağkalım oranlarını değerlendirmeyi amaçladıkGereç ve Yöntem: Çalışmaya retrospektif olarak 2014-2022 yılları arasında kolon rezeksiyonu yapılan 146 hasta dahil edildi. MSI durumu, immünohistokimyal belirteçlerle değerlendirildi. MSI durumu, tümörü infiltre eden lenfositlerin (TIL'ler) varlığı ve tümör tomurcuklanma skorunun sağkalım ile olan ilişkisi, Kaplan-Meier yöntemi ve Cox regresyon analizi ile değerlendirildi.Bulgular: Olgularımızın 104’ü (%71,2) MSS, 42’si (%28,8) MSİ’dir. MSI tümörlerin 15’i (%10,3) MSI-düşük, 27’si (%18,5) MSİ-yüksek olarak bulundu. MSİ tümörler, genç yaş (<50 yaş), erken evre (T1-T2), sağ kolon lokalizasyonu, düşük lenf nodu metastazı oranı, müsinöz komponent ve TİL varlığı ile istatistiksel olarak anlamlı şekilde ilişkiliydi. Cox-regresyon modeli, TIL'lerin, tümör tomurcuklanma skorunun ve MSİ'nin sağkalımı önemli ölçüde etkileyen değişkenler olduğunu ortaya çıkardı. TIL'lerin varlığı, takip süresince ölüm riskini 2,24 kat azaltan koruyucu bir etki (Tehlike oranı (HR)=0,446) sergilerken, yüksek tümör tomurcuklanma skorunun ölüm riskini (HR=3,22) artırdığı bulundu.Sonuç: Çalışmamızda, MSİ KRK’li hastaların, kendilerine özgü klinikopatolojik özellikler gösterebileceği ve sağkalımda yol gösterici bazı parametrelerle birlikte değerlendirilmesi gerektiği vurgulanmaktadır.

🔖

Cite This Article

TOYRAN, T., ERDOGAN, K., BAĞIR, E. K., AÇIKALIN, A., AKSIN, M., PAYDAŞ, S., METE, B., ERDOGAN, S. (2023). Effect of microsatellite instability on histopathological parameters and prognosis in colon cancers. Cukurova Medical Journal, Cilt: 48 - Sayı: 1, 1–10. https://ajindex.com/articles/885368

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;70:313
  2. Zhang C, Cui M, Xing J, Yang H, Yao Z, Zhang N. et al. Clinicopathologic features and prognosis of synchronous and metachronous multiple primary colorectal cancer. Clin Transl Oncol. 2021;23:335-43
  3. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004;126:394-401
  4. Corti C, Sajjadi E, Fusco N. Determination of mismatch repair status in human cancer and its clinical significance: does one size fit all? Adv Anat Pathol. 2019; 26:270-79
  5. Kawakami H, Zaanan A, and Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr Treat Options Oncol. 2015;16:1-15
  6. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and lynch syndrome. Histopathology. 2010;56:167-79
  7. Umar A, Boland CR, Terdiman JP, Syngal S, Chapelle ADL, Rüschoff J et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-68
  8. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam cancer. 2004;3:93-100
  9. El Agy F, Otmani IE, Mazti A, Lahmidani N, Oussaden A, El Abkari M et al. Implication of microsatellite instability pathway in outcome of colon cancer in Moroccan population. Dis Markers. 2019
  10. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol. 2010;7:197-208
  11. Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299-311
  12. Taieb J, Le Malicot K, Shi Q, Penault-Llorca F, Bouche O, Tabernero J et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. JNCI: J Natl Cancer Inst. 2017;109
  13. Whitehall V, Leggett B. Microsatellite instability: detection and management in sporadic colorectal cancer. J Gastroenterol Hepatol. 2011;26:1697-9
  14. Chapusot C